Aradigm to Present at the 10th Annual BIO Investor Forum on October 26

HAYWARD, Calif.--(BUSINESS WIRE)-- Aradigm Corporation (OTCBB:ARDM) (the “Company”) today announced that President and Chief Executive Officer Igor Gonda, Ph.D., will present at the 2011 Annual BIO Investor Forum on Wednesday, October 26, 2011, at 11:00 a.m. Pacific time.

The event will be held at the Palace Hotel in San Francisco, CA.

Interested parties can access a live audio webcast and slide presentation at www.aradigm.com. An archived presentation will be available on the Company’s Web site for 14 days.

About the BIO Investor Forum

The 10th Annual BIO Investor Forum, hosted by the Biotechnology Industry Organization (BIO), is an international conference featuring late-stage private and emerging public companies. The BIO Investor Forum will include healthcare venture and private equity investors, buy-side investors, and research analysts as well as business development executives from leading global pharmaceutical and biotechnology companies.

About Aradigm

Aradigm is an emerging specialty pharmaceutical company focused on the development and commercialization of a portfolio of drugs delivered by inhalation for the treatment of severe respiratory diseases by pulmonologists. The Company has product candidates addressing the treatment of bronchiectasis, cystic fibrosis, inhalation tularemia and anthrax infections, and smoking cessation.

More information about Aradigm can be found at www.aradigm.com.

Aradigm and the Aradigm Logo are registered trademarks of Aradigm Corporation.



CONTACT:

Aradigm Corporation
Nancy Pecota, 510-265-8800
Chief Financial Officer

KEYWORDS:   United States  North America  California

INDUSTRY KEYWORDS:   Health  Biotechnology  Infectious Diseases  Pharmaceutical

MEDIA:

Logo
 Logo

Suggested Articles

German researchers uncovered 28 antibodies that neutralize COVID-19 and are working with Boehringer Ingelheim to advance them into clinical testing.

Oragenics is ending a phase 2 study of its oral mucositis drug, yanking its IND application and switching its focus to a COVID-19 vaccine.

The vehicle, which Blackstone claims is the largest life sciences private fund, has committed close to $1 billion to companies including Alnylam.